DURHAM, NC – (COMMERCIAL THREAD) – Xilis, Inc., a pioneering company using its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, today announced the closing of funding from Series A of $ 70 million. The round was led by Mubadala Capital, joined by new investors including GV (formerly Google Ventures), LSP (one of Europe’s largest healthcare investment firms), Catalio Capital Management and Duke Angel Network. Current investors Felicis Ventures, Two Sigma Ventures, Pear VC, KdT Ventures and Alix Ventures also participated.
Founded in 2019 by Dr Xiling Shen, Dr David Hsu and Dr Hans Clevers, Xilis draws on decades of biomedical, oncology and stem cell research by its three co-founders. Breakthrough Award winner Dr Clevers is the inventor and pioneer of organoid technology. Dr Shen and Dr Hsu are accomplished engineering and medicine professors at Duke University and experts in precision medicine. They developed scalable MOS technology to analyze patient tumors in their native microenvironment – a revolutionary achievement.
“Our vision is to transform cancer care into diagnostics and reshape drug development by providing rapid therapeutic profiling technology,” said Xiling Shen, PhD, Founder and CEO of Xilis. “The support provided by these world-class investors is an important step in our journey to transform cancer care and dramatically improve patient survival by enabling personalized precision oncology and bringing transformative medicines to patients faster and with greater efficiency. higher success rates, ”added Dr. Shen.
Hans Clevers, MD, PhD, Scientific Co-Founder, Venture Capital Partner at LSP and Principal Investigator at the Hubrecht Institute, The Netherlands, said: “Since my lab invented organoids a dozen ago years, we have provided proof of concept for many applications, yet the technology has remained slow, complex and expensive. In collaboration with LSP, I searched for an enabling technology to unleash the full potential, and the invention of MOS technology by Dr Shen and Dr Hsu removed these barriers and will accelerate its use both in the clinic and for drug discovery and development. . ”
Xilis MOS has been proven to have wide applications:
Leveraging MOS and AI algorithms, Xilis is developing its precision oncology platform to accurately predict therapeutic responses to help clinicians prioritize cancer treatment strategies for each patient. The entire process, from the patient’s biopsy to the results, takes less than two weeks, allowing for extensive clinical application.
MOS technology enables the discovery and development of high fidelity pharmaceutical drugs. Drug developers can use this versatile platform at multiple stages of R&D, including early discovery, preclinical toxicity and efficacy, bioanalytical testing, and clinical trials.
MOS is a revolutionary technology for the development of immunotherapy, which requires the immune microenvironment of the patient.
Proceeds from the Series A funding will advance Xilis’ proprietary MOS technology, expand its AI-based capabilities, fund clinical studies for diagnostic development, and validate the use of MOS technology with biopharmaceutical partners.
“There is a critical need for technologies that can help clinicians determine the most optimal therapy for their individual patients,” added Ayman AlAbdallah of Mubadala Capital. “Patients will benefit greatly from Xilis precision medicine testing by avoiding spending time on ineffective treatment cycles and instead receiving therapies with the greatest potential for success quickly and effectively. The Xilis Precision Oncology Platform is a cost-effective, results-driven advancement that will help reduce the global burden of oncology costs. ”
“Genetic approaches to cancer diagnosis continue to have an impact and Xilis is creating significant pathways for its precision oncology platform to improve cancer care for more patients,” said the Managing Partner of GV, Krishna Yeshwant, MD, MBA. “Xilis brings together experts in the fields of organoid development and precision medicine, and I am delighted to work with this impressive team as they continue to develop a revolutionary approach.
Based in Durham, North Carolina, Xilis, Inc. is a biotechnology company developing a precision oncology platform that guides treatment decisions for oncologists to improve cancer care outcomes for patients. and supports drug discovery and development for pharmaceutical companies. Xilis’s proprietary MicroOrganoSphere ™ (MOS) technology consists of miniature patient tumors that capture the entire microenvironment and heterogeneity and provide an automated and scalable solution. Using algorithms driven by MOS and AI, Xilis is developing an Xilis ™ response score for the clinic, enabling oncologists to make informed and timely treatment decisions. Additionally, MOS technology accelerates the development and clinical trials of anticancer drugs by enabling analysis of authentic tumor microenvironments, high throughput preclinical modeling and clinical patient selection capabilities.
About the capital Mubadala
Mubadala Capital is the asset management arm of Mubadala Investment Company, a leading global sovereign investor headquartered in Abu Dhabi. In addition to managing its own balance sheet investments, Mubadala Capital manages third party capital on behalf of institutional investors in four of its businesses, including three private equity funds, two early stage venture capital funds, one public fund and a fund in Brazil focused on specific situations. The different companies invest through the capital structure in public and private securities.
To learn more about Xilis, visit our website at www.Xilis.com or follow us on Twitter and LinkedIn.